NasdaqCM - Delayed Quote USD

Avenue Therapeutics, Inc. (ATXI)

Compare
2.2400 -0.1800 (-7.44%)
At close: November 1 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Alexandra MacLean M.D. CEO & Director 413.2k -- 1967
Mr. David Jin Interim CFO, COO & Corporate Secretary -- -- 1990
Dr. Lindsay Allan Rosenwald Executive Director -- -- 1955
Dr. Scott A. Reines M.D., Ph.D. Interim Chief Medical Officer 69.12k -- 1947

Avenue Therapeutics, Inc.

1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154
United States
781 652 4500 https://www.avenuetx.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
3

Description

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Corporate Governance

Avenue Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 11, 2024 at 10:59 AM UTC - November 15, 2024 at 12:00 PM UTC

Avenue Therapeutics, Inc. Earnings Date

Recent Events

September 27, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 9, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

July 12, 2024 at 12:00 AM UTC

S-8: Offering Registrations

June 26, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 23, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 15, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 13, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 6, 2024 at 12:00 AM UTC

S-3: Offering Registrations

May 1, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 26, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers